Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avacopan in Children With Active ANCA-associated Vasculitis
NCT06321601Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Oct 2024
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of avacopan in Antineutrophil cytoplasmic antibody-associated vasculitis (AAV), sponsored by Amgen. Started Oct 2024; status: active, not recruiting.
02
Drugs
avacopan
03
Conditions
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT06321601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06321601.